研究者詳細 - 今井　則博

論文 - 今井　則博

分割表示 112 件中 101 - 112 件目／全件表示 >>

A case of intractable hepatic encephalopathy successfully treated by oral administration of vancomycin hydrochloride, with subsequent improvement of hepatic function reserve enabling transcatheter arterial chemoembolization against hepatocellular carcinoma

Kuzuya T.

Japanese Journal of Cancer and Chemotherapy 38 巻 ( 6 ) 頁： 995 - 997 2011年6月

Clearance of hepatitis b surface antigen during long-term nucleot(s)ide analogues treatment in chronic hepatitis B

Hosaka T

Acta Hepatologica Japonica 52 巻 ( 4 ) 頁： 255 - 257 2011年6月

掲載種別：研究論文（学術雑誌）出版者・発行元：Acta Hepatologica Japonica

Clearance of HBsAg is considered the ultimate goal in the treatment for chronic hepatitis B. We analyzed clinical factors associated with HBsAg clearance during long-term nucleot(s)ide analogue treatment. By univariate analysis, HBV genotype, family history of HBV infection, previous IFN therapy, HBeAg clearance at 6 months, and undetectable HBV DNA at 6 months were significant predictive factors. By multivariate analysis, HBV genotype, previous IFN therapy, HBeAg clearance at 6 months, and undetectable HBV DNA at 6 months were independent and significant predictive factors of HBsAg clearance. We conclude that patients with genotype A have high probability of HBsAg clearance, and it seems that not only the antiviral potential of nucleot(s)ide analogue but host immune response is needed to achieve HBsAg clearance.

DOI： 10.2957/kanzo.52.255

Scopus

researchmap

Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus

Arase Y

Hepatology Research 41 巻 ( 6 ) 頁： 524 - 529 2011年6月

Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model.

Ikeda K, Kobayashi M, Kawamura Y, Imai N, Seko Y, Hirakawa M, Hosaka T, Sezaki H, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H

Liver international : official journal of the International Association for the Study of the Liver 31 巻 ( 5 ) 頁： 692 - 9 2011年5月

Effect of early antiviral agent therapy (NS3 and NS5A inhibitors) in chronic hepatitis C null responders

Suzuki Y

Acta Hepatologica Japonica 52 巻 ( 2 ) 頁： 147 - 149 2011年4月

掲載種別：研究論文（学術雑誌）出版者・発行元：Acta Hepatologica Japonica

To further improve therapeutic effect on chronic hepatitis C, we have administered NS3 inhibitor and NS5A inhibitor together, and examined effects of early antiviral agent therapy. The subjects were five cases where interferon is ineffective (null responders). The NS5A and NS3 inhibitors are oral drugs and were daily administered for 24 weeks. Figure 1 shows time-dependent change of the number of viruses after the therapy started, and rapid decrease of viruses is recognized. Within 12 hours, HCV-RNA decreased by more than 2 log IU/ml in every patient. Two patients became negative for the virus by the 15th day after the therapy started. Furthermore, 80% of cases by the 28th day and all the cases by the 56th day became negative. The new therapy has manifested excellent early antiviral effect.

DOI： 10.2957/kanzo.52.147

Scopus

researchmap

Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients.

Arase Y, Suzuki Y, Suzuki F, Matsumoto N, Akuta N, Imai N, Seko Y, Sezaki H, Kawamura Y, Kobayashi M, Hosaka T, Saito S, Ikeda K, Kobayashi M, Kumada H

Internal medicine (Tokyo, Japan) 50 巻 ( 19 ) 頁： 2083 - 8 2011年

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Internal Medicine

Objective The aim of this study was to evaluate the efficacy and safety of combination therapy of natural human interferon-beta and ribavirin for patients for whom prior interferon therapy was discontinued due to depression induced by interferon-alpha. Methods Inclusion criteria were as follows; 1) HCV-genotype 1b, 2) serum HCV RNA level of ≥100 KIU/mL, 3) stopping the prior interferon-alpha monotherapy or combination therapy of interferon-alpha and ribavirin due to the appearance of depression. A total of 14 were enrolled in this prospective cohort study. The treatment period of combination therapy was 48 weeks. Depression states, reflected by Beck depression inventories and Hamilton depression rating scale, were assessed during combination therapy. Nonparametric procedures were employed for the analysis of background features of the patients with sustained virological response (SVR) and without SVR. A p value of <0.05 was considered to indicate a significant difference. Results Five of 14 patients (37.5%) had SVR by the intention to treat analysis. The SVR rate in patients who showed negative HCV RNA at 12 and 24 weeks after the initiation of combination therapy was 100% (4/4) and 83.3% (5/6), respectively. All of the patients continued the combination therapy owing to disappearance of severely adverse events contained the exacerbation of depression. Combination therapy did not yield a statistical difference in Beck depression inventories and Hamilton depression rating scale. Conclusion The combination therapy of IFN-beta and ribavirin is a possible therapy selection for the patients for whom interferon therapy was discontinued due to depression induced by interferon-alpha.

DOI： 10.2169/internalmedicine.50.5767

Scopus

PubMed

researchmap

Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.

Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H

Oncology 80 巻 ( 3-4 ) 頁： 188 - 94 2011年

Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation : A retrospective study of hepatitis C virus-related liver cancer

IKEDA Kenji, KOBAYASHI Masahiro, SEKO Yuya, IMAI Norihiro, HIRAKAWA Miharu, KAWAMURA Yusuke, SEZAKI Hitomi, HOSAKA Tetsuya, AKUTA Norio, SAITOH Satoshi, SUZUKI Fumitaka, SUZUKI Yoshiyuki, ARASE Yasuji, KUMADA Hiromitsu

Hepatology research : the official journal of the Japan Society of Hepatology 40 巻 ( 12 ) 頁： 1168-1175 2010年12月

Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and child-pugh B liver cirrhosis

Imai N

Acta Hepatologica Japonica 51 巻 ( 12 ) 頁： 758 - 760 2010年12月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Acta Hepatologica Japonica

Miriplatin is a novel lipophilic platinum complex developed to treat hepatocellular carcinoma (HCC). Although HCC patients frequently have coexisting severe liver cirrhosis, there is no prospective data regarding clinical toxicity of miriplatin in HCC patients with severe cirrhosis. We retrospectively evaluated the safety and efficacy of transcatheter arterial chemotherapy with miriplatin in 34 HCC patients with severe liver cirrhosis (Child-Pugh grade B). An anti-tumor effect of complete response was achieved in 8 of 34 patients and no serious adverse events were observed. These results suggested that transcatheter arterial chemotherapy with miriplatin can be used safety for HCC patients with Child-Pugh B liver cirrhosis.

DOI： 10.2957/kanzo.51.758

Scopus

researchmap

A case of metastatic pancreatic cancer with a remarkable response to combination therapy of gemcitabine and adoptive immune cell therapy

Imai N.

Japanese Journal of Cancer and Chemotherapy 37 巻 ( 3 ) 頁： 527 - 529 2010年3月

High Incidence of Colonic Perforation During Colonoscopy in Hemodialysis Patients With End-Stage Renal Disease

Imai Norihiro, Takeda Kinichi, Kuzuya Teiji, Utsunomiya Setsuo, Takahashi Hiroshi, Kasuga Hirotake, Asai Masami, Yamada Michiko, Tanikawa Yutaka, Goto Hidemi

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 8 巻 ( 1 ) 頁： 55 - 59 2010年1月

A case of hepatitis b-related multiple hepatocellular carcinomas, most of which lead to necrosis possibly due to the implantation of an arterial infusion catheter

Kuzuya T.

Japanese Journal of Cancer and Chemotherapy 36 巻 ( 12 ) 頁： 2377 - 2379 2009年11月

　前のページ - 次のページ　

<今井 則博>

論文 - 今井 則博

<今井　則博>

論文 - 今井　則博